New leukemia drug tested in kids: could it mean fewer shots?
NCT ID NCT01574274
Summary
This study is testing a new, longer-lasting version of a standard chemotherapy drug (asparaginase) for children and teens with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. Researchers want to see if giving this new drug, called SC-PEG, every 3 weeks into a vein works as well and is as safe as the standard drug, Oncaspar, given every 2 weeks. The study also tests if adjusting treatment based on very sensitive disease measurements, giving preventive antibiotics, and checking vitamin D levels can help improve outcomes and reduce side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier U. de Quebec
Québec, Quebec, Canada
-
Children's Hospital Boston
Boston, Massachusetts, 02215, United States
-
Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hasbro Children's Hospital
Providence, Rhode Island, 02903, United States
-
Hospital Sainte Justine, University of Montreal
Montreal, Quebec, Canada
-
McMaster University
Hamilton, Ontario, Canada
-
Montefiore Medical Center
New York, New York, 10467, United States
Conditions
Explore the condition pages connected to this study.